Sustained FVIII Expression and Phenotypic Correction of Hemophilia A in Neonatal Mice Using an Endothelial-Targeted Sleeping Beauty Transposon
Open Access
- 31 May 2006
- journal article
- research article
- Published by Elsevier in Molecular Therapy
- Vol. 13 (5), 1006-1015
- https://doi.org/10.1016/j.ymthe.2005.11.021
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Increased Maintenance and Persistence of Transgenes by Excision of Expression Cassettes from Plasmid SequencesIn VivoHuman Gene Therapy, 2005
- A direct comparison of two nonviral gene therapy vectors for somatic integration: in vivo evaluation of the bacteriophage integrase ϕC31 and the Sleeping Beauty transposaseMolecular Therapy, 2005
- Phenotypic correction and long-term expression of factor VIII in hemophilic mice by immunotolerization and nonviral gene transfer using the Sleeping Beauty transposon systemBlood, 2005
- A review of gene therapy for haematological disordersBritish Journal of Haematology, 2004
- Prophylactic factor replacement in hemophiliaBlood Reviews, 2004
- Induction of immune tolerance by neonatal intravenous injection of human factor VIII in murine hemophilia AJournal of Thrombosis and Haemostasis, 2004
- Nonviral Gene Therapy Approaches to HemophiliaSeminars in Thrombosis and Hemostasis, 2004
- Site-specific genomic integration produces therapeutic Factor IX levels in miceNature Biotechnology, 2002
- Dangerous liaisons: the role of “danger” signals in the immune response to gene therapyBlood, 2002
- Induction of Immunity to Antigens Expressed by Recombinant Adeno-Associated Virus Depends on the Route of AdministrationClinical Immunology, 1999